Related Experiment Videos
Agranulocytosis during treatment with fluconazole
H Murakami1, H Katahira, T Matsushima
1Third Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
The Journal of International Medical Research
|November 1, 1992
Summary
Fluconazole, an antifungal, can cause rare but serious blood disorders like agranulocytosis and thrombocytopenia. Patients require careful blood monitoring during fluconazole treatment due to potential hematologic adverse reactions.
Area of Science:
- Pharmacology
- Hematology
- Mycology
Background:
- Fluconazole is a widely used triazole antifungal agent.
- It is generally associated with fewer adverse reactions compared to amphotericin B.
Observation:
- A patient developed agranulocytosis and thrombocytopenia.
- These hematologic conditions occurred during fluconazole therapy.
Findings:
- The patient recovered after fluconazole treatment was discontinued.
- This indicates a potential causal link between fluconazole and the observed blood disorders.
Implications:
- Highlights the importance of vigilant hematological monitoring in patients receiving fluconazole.
- Suggests a need for increased awareness of potential severe adverse drug reactions to fluconazole.